Skip to main content
. 2017 Jul 26;37(10):937–946. doi: 10.1007/s40261-017-0548-6

Table 5.

Summary of adverse events

Event DFN-15
120 mg
(n  =  15)
DFN-15
180 mg
(n  =  15)
DFN-15
240 mg
(n  =  16)
Oral capsules
400 mg
(n  =  15)
Subjects with one or more AE 0 0 1 (6.3) 0
Investigations 0 0 1 (6.3) 0
Hemoglobin decreased 0 0 1 (6.3) 0
Occult blood positive 0 0 1 (6.3) 0

Data are presented as n (%)

AE adverse event